Talinolol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Talinolol
Accession Number
DB11770
Type
Small Molecule
Groups
Investigational
Description

Talinolol has been investigated for the basic science of Gastrointestinal Motility Disorder.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
3S82268BKG
CAS number
57460-41-0
Weight
Average: 363.4943
Monoisotopic: 363.252191937
Chemical Formula
C20H33N3O3
InChI Key
MXFWWQICDIZSOA-UHFFFAOYSA-N
InChI
InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)
IUPAC Name
N-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N'-cyclohexylcarbamimidic acid
SMILES
CC(C)(C)NCC(O)COC1=CC=C(NC(O)=NC2CCCCC2)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Talinolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Talinolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Talinolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Talinolol.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Talinolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Talinolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Talinolol can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Talinolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Talinolol.Approved
AcetohexamideTalinolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Talinolol is combined with Acetylcholine.Approved
AcetyldigitoxinTalinolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinTalinolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Talinolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Talinolol.Experimental, Investigational
AlaproclateThe serum concentration of Talinolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Talinolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Talinolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Talinolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Talinolol.Approved, Vet Approved
AliskirenAliskiren may increase the hypotensive activities of Talinolol.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Talinolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Talinolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Talinolol.Approved
AmbrisentanTalinolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTalinolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmiodaroneThe therapeutic efficacy of Talinolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Talinolol.Approved
AmobarbitalThe serum concentration of Talinolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Talinolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Talinolol.Approved, Illicit, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Talinolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Talinolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Talinolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Talinolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Talinolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Talinolol is combined with Arecoline.Experimental
AtenololAtenolol may increase the hypotensive activities of Talinolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Talinolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Talinolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Talinolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Talinolol.Approved, Investigational
BarbexacloneThe serum concentration of Talinolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Talinolol can be decreased when it is combined with Barbital.Illicit
BarnidipineTalinolol may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Talinolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Talinolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Talinolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Talinolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Talinolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Talinolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Talinolol.Approved
BepridilBepridil may increase the hypotensive activities of Talinolol.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Talinolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Talinolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Talinolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Talinolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Talinolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Talinolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Talinolol.Investigational
BosentanBosentan may increase the hypotensive activities of Talinolol.Approved, Investigational
BQ-123Talinolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Talinolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Talinolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Talinolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Talinolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Talinolol.Investigational
BucindololTalinolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Talinolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Talinolol.Experimental
BunazosinTalinolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Talinolol.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Talinolol.Approved
CabergolineTalinolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Talinolol.Experimental
CafedrineTalinolol may increase the hypotensive activities of Cafedrine.Investigational
CandesartanTalinolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Talinolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Talinolol.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Talinolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Talinolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Talinolol.Experimental, Investigational
CarbutamideTalinolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Talinolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Talinolol.Approved
CarvedilolTalinolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Talinolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Talinolol.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Talinolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Talinolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Talinolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Talinolol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Talinolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Talinolol.Approved, Investigational, Vet Approved
ChlorpropamideTalinolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Talinolol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Talinolol.Approved
CicletanineTalinolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Talinolol.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Talinolol.Approved
CloranololTalinolol may increase the hypotensive activities of Cloranolol.Experimental
CoumaphosCoumaphos may increase the bradycardic activities of Talinolol.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Talinolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Talinolol.Approved, Investigational
CyclopenthiazideTalinolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Talinolol.Approved
CymarinTalinolol may increase the bradycardic activities of Cymarin.Experimental
DapoxetineThe serum concentration of Talinolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Talinolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Talinolol.Approved
DelaprilTalinolol may increase the hypotensive activities of Delapril.Experimental
DemecariumDemecarium may increase the bradycardic activities of Talinolol.Approved
DeserpidineTalinolol may increase the hypotensive activities of Deserpidine.Approved
DeslanosideTalinolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Talinolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Talinolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Talinolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Talinolol.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Talinolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Talinolol.Approved, Investigational
DigitoxinTalinolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinTalinolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Talinolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Talinolol.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Talinolol.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Talinolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Talinolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Talinolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Talinolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Talinolol.Approved
DoxazosinTalinolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Talinolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Talinolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
DuloxetineThe serum concentration of Talinolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Talinolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Talinolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Talinolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Talinolol.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Talinolol.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Talinolol.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Talinolol.Approved
EndralazineEndralazine may increase the hypotensive activities of Talinolol.Experimental
EpanololTalinolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Talinolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Talinolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Talinolol.Approved
EprosartanEprosartan may increase the hypotensive activities of Talinolol.Approved
Ergoloid mesylateTalinolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineTalinolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Talinolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Talinolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Talinolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
EtoperidoneThe serum concentration of Talinolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Talinolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Talinolol.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Talinolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Talinolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Talinolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Talinolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Talinolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Talinolol.Approved
FentanylFentanyl may increase the bradycardic activities of Talinolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Talinolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Talinolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Talinolol.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Talinolol.Experimental
FingolimodTalinolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Talinolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Talinolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Talinolol.Experimental
FluoxetineThe serum concentration of Talinolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Talinolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Talinolol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Talinolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Talinolol.Approved, Investigational, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Talinolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Talinolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Talinolol.Approved, Investigational, Nutraceutical
GitoformateTalinolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideTalinolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideTalinolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTalinolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTalinolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneTalinolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideTalinolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideTalinolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Talinolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Talinolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Talinolol.Approved
GuanazodineTalinolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Talinolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
GuanoclorTalinolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTalinolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTalinolol may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Talinolol.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of Talinolol.Experimental
HexobarbitalThe serum concentration of Talinolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Talinolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Talinolol.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Talinolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Talinolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Talinolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Talinolol.Approved, Investigational
HydroxychloroquineThe metabolism of Talinolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Talinolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Talinolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Talinolol.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Talinolol.Approved, Investigational
ImidaprilTalinolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Talinolol.Experimental
IndalpineThe serum concentration of Talinolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Talinolol.Approved
IndenololIndenolol may increase the hypotensive activities of Talinolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Talinolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Talinolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Talinolol.Withdrawn
IndoraminTalinolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanTalinolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkTalinolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Talinolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Talinolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Talinolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Talinolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Talinolol.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Talinolol.Approved, Investigational, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Talinolol.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Talinolol.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Talinolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Talinolol.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Talinolol.Approved
LabetalolTalinolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineLacidipine may increase the hypotensive activities of Talinolol.Approved, Investigational
Lanatoside CTalinolol may increase the bradycardic activities of Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Talinolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Talinolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Talinolol.Approved, Investigational
LevomilnacipranThe serum concentration of Talinolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Talinolol.Approved, Vet Approved
LinsidomineTalinolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Talinolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Talinolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Talinolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Talinolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Talinolol.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Talinolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Talinolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Talinolol.Approved, Investigational
MacitentanTalinolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Talinolol.Approved
MalathionMalathion may increase the bradycardic activities of Talinolol.Approved, Investigational
ManidipineManidipine may increase the hypotensive activities of Talinolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Talinolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Talinolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Talinolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Talinolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Talinolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Talinolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Talinolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Talinolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Talinolol.Approved, Investigational
MetahexamideTalinolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Withdrawn
MethacholineTalinolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Talinolol.Investigational
MethohexitalThe serum concentration of Talinolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineTalinolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Talinolol.Approved, Investigational
MethyldopaMethyldopa may increase the hypotensive activities of Talinolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Talinolol.Approved, Investigational
MethylergometrineTalinolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Talinolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Talinolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinTalinolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Talinolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Talinolol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Talinolol.Approved
MetoprololMetoprolol may increase the hypotensive activities of Talinolol.Approved, Investigational
MetyrosineTalinolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Talinolol.Investigational, Withdrawn
MidodrineTalinolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Talinolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Talinolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Talinolol.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Talinolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Talinolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Talinolol.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Talinolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Talinolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Talinolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Talinolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
MuzolimineTalinolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Talinolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Talinolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Talinolol.Approved
NadololNadolol may increase the hypotensive activities of Talinolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Talinolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Talinolol.Approved
NaftopidilTalinolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Talinolol.Approved, Investigational
NefazodoneThe serum concentration of Talinolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Talinolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Talinolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Talinolol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Talinolol.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Talinolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Talinolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Talinolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Talinolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Talinolol.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Talinolol.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Talinolol.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Talinolol.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Talinolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Talinolol.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Talinolol.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Talinolol.Approved, Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
ObinutuzumabTalinolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Talinolol.Withdrawn
OleandrinTalinolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Talinolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Talinolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Talinolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Talinolol.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Talinolol.Vet Approved
OuabainTalinolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Talinolol.Approved
OxprenololOxprenolol may increase the hypotensive activities of Talinolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Talinolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Talinolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Talinolol.Approved
PargylinePargyline may increase the hypotensive activities of Talinolol.Approved
ParoxetineThe serum concentration of Talinolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Talinolol.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Talinolol.Approved, Investigational
PentobarbitalThe serum concentration of Talinolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Talinolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Talinolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Talinolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Talinolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Talinolol.Approved
PeruvosideTalinolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Talinolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Talinolol.Withdrawn
PhenobarbitalThe serum concentration of Talinolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Talinolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Talinolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Talinolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Talinolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Talinolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Talinolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Talinolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Talinolol.Approved
PindololPindolol may increase the hypotensive activities of Talinolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Talinolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Talinolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Talinolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Talinolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Talinolol.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Talinolol.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Talinolol.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Talinolol.Experimental, Investigational
PrazosinTalinolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Talinolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Talinolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Talinolol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Talinolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Talinolol.Experimental
PromazinePromazine may increase the hypotensive activities of Talinolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Talinolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Talinolol.Approved, Investigational
PropafenoneThe serum concentration of Talinolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Talinolol.Approved, Investigational
PropiopromazinePropiopromazine may increase the hypotensive activities of Talinolol.Vet Approved
PropranololPropranolol may increase the hypotensive activities of Talinolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Talinolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Talinolol.Experimental
ProscillaridinTalinolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Talinolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Talinolol.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of Talinolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Talinolol.Approved
RamiprilRamipril may increase the hypotensive activities of Talinolol.Approved
RasagilineRasagiline may increase the hypotensive activities of Talinolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Talinolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Talinolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Talinolol.Approved
RescinnamineTalinolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Talinolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Talinolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Talinolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Talinolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Talinolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Talinolol.Approved, Investigational
RiociguatTalinolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
RituximabTalinolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineTalinolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Talinolol.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Talinolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Talinolol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Talinolol.Experimental
SecobarbitalThe serum concentration of Talinolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Talinolol.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Talinolol.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Talinolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Talinolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Talinolol.Investigational
SertralineThe serum concentration of Talinolol can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Talinolol.Approved, Investigational
SilodosinTalinolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanTalinolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Talinolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Talinolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Talinolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Talinolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Talinolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Talinolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Talinolol.Experimental
TacrineTacrine may increase the bradycardic activities of Talinolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Talinolol.Approved, Investigational
TamsulosinTalinolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Talinolol.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Talinolol.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Talinolol.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Talinolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Talinolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Talinolol.Vet Approved
TerazosinTalinolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Talinolol.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Talinolol.Approved, Investigational
TetrahydropalmatineTalinolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineTalinolol may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe serum concentration of Talinolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Talinolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Talinolol.Withdrawn
ThiopentalThe serum concentration of Talinolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Talinolol.Approved
ThioridazineThioridazine may increase the hypotensive activities of Talinolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Talinolol.Approved
TiboloneTibolone may increase the hypotensive activities of Talinolol.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Talinolol.Withdrawn
TimololTimolol may increase the hypotensive activities of Talinolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Talinolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
TolazamideTalinolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Talinolol.Approved, Vet Approved
TolbutamideTalinolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Talinolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Talinolol.Approved
TolonidineTalinolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Talinolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Talinolol.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Talinolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Talinolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Talinolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Talinolol.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Talinolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Talinolol.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Talinolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Talinolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Talinolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Talinolol.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Talinolol.Approved, Vet Approved
TrimazosinTalinolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Talinolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Talinolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Talinolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Talinolol.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Talinolol.Approved, Investigational
UrapidilTalinolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Talinolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Talinolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Talinolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Talinolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Talinolol.Approved
VincamineTalinolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTalinolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideTalinolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Talinolol.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Talinolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Talinolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Talinolol can be increased when it is combined with Zimelidine.Withdrawn
ZofenoprilTalinolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Talinolol.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB42020
PubChem Compound
68770
PubChem Substance
347828123
ChemSpider
62014
ChEBI
135533
ChEMBL
CHEMBL152067
ATC Codes
C07AB13 — Talinolol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceGenotype-related Drug Metabolism1
1CompletedBasic ScienceObesity, Morbid1
1CompletedBasic ScienceUpper gastrointestinal motility disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0593 mg/mLALOGPS
logP3.29ALOGPS
logP2.3ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)8.62ChemAxon
pKa (Strongest Basic)9.79ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area86.11 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity104.99 m3·mol-1ChemAxon
Polarizability42.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-phenylureas. These are compounds containing a N-phenylurea moiety, which is structurally characterized by a phenyl group linked to one nitrogen atom of a urea group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
N-phenylureas
Direct Parent
N-phenylureas
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Ureas / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
N-phenylurea / Phenoxy compound / Phenol ether / Alkyl aryl ether / 1,2-aminoalcohol / Urea / Secondary alcohol / Carbonic acid derivative / Secondary aliphatic amine / Ether
show 12 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:46 / Updated on November 09, 2017 04:56